anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Endometrial cancer (EC) is the second most common malignant tumor of the female reproductive system, and it occurs in the peri- and post-menopausal periods. The metastasis routes of EC include direct spread, hematogenous metastasis and lymph node metastasis. Symptoms such as vaginal discharge or irregular vaginal bleeding may occur in the early stage. The pathological stage of the patients treated at this time is mostly in the early stage, and comprehensive treatment such as surgery, radiotherapy and chemotherapy can improve the prognosis. This article investigates whether endometrial cancer requires pelvic and para-aortic lymph node dissection. The clinical data of 228 patients with endometrial cancer who underwent pelvic lymphadenectomy in our hospital from July 2020 to September 2021 were retrospectively analyzed. All patients underwent preoperative clinical staging and postoperative pathological staging. This paper compared lymph node spread rates of endometrial carcinoma in different stages, depth of muscle invasion, and pathological characteristics to analyze lymph node metastasis risk factors. Results showed metastasis rates of 7.5% in 228 cases of endometrial cancer, increasing with deeper myometrial invasion. Different clinicopathological factors had varying lymph node spread rates. Different clinicopathological factors have different pelvic lymph node spread rates in surgical patients. The lymph node spread rate of differentially differentiated carcinoma is higher than that of well-differentiated carcinoma. The lymph node spread rate of serous carcinoma is 100%, but there is no difference between the lymph node metastasis rate of special type carcinoma and adenocarcinoma. Statistical significance (P > 0.05).
This is an open-label, dose-escalating clinical trial. Three groups of four patients will receive transplants of increasing doses of HLA-matched umbilical cord blood mononuclear cell into the spinal cord. In the fourth group, we will transplant the highest volume of cells that did not increase neurological deficits along with a single bolus of 30mg/kg methylprednisolone sodium succinate. In the fifth group of four subjects, we will inject that volume of cells plus a bolus intravenous dose of 30mg/kg methylprednisolone sodium succinate and a 6-week course of oral lithium carbonate titrated to 0.6-1.0 mM serum levels. All the subjects are encouraged to stand or walk for one hour a day after the cell transplantation.

The neurological and walking outcomes will be assessed 1, 2, 6, 24 and 48 weeks after transplantation. The outcomes of the five treatment groups will be compared by analysis of variance and, if possible, correlation with cell dose. Efficacy and safety will be analyzed comparing neurological change scores amongst the five different treatment groups. Loss of motor (\>5 points) or sensor scores (\>2 points) from baseline pre-treatment levels would be considered deleterious. Increases in scores above baseline would be considered beneficial.
<P>PROBLEM TO BE SOLVED: To provide a hair dedyeing agnet composition with sufficient operability and dedyeing power.  <P>SOLUTION: The hair dedyeing agent composition is prepared by mixing a first agent and a second agent just before being used; the resultant mixture is applied to dyed hair to dedye it. The first agent is a liquid or gel composition; the second agent, a solid composition. The first agent contains (A) at least one kind of gum selected from karaya gum and tragacanth gum and (B) water; the second agent contains at least one compound selected from (C) ascorbic acid and its derivatives. Preferably, the first agent further contains, as component (D), a water-soluble polymer compound other than component (A), component (D) preferably being carboxymethylcellulose. Preferably, the second agent further contains (E) fumaric acid.  <P>COPYRIGHT: (C)2004,JPO
Human Overdose Experience: Human experience of acute overdose with tiagabine HCl is limited. Eleven patients in clinical trials took single doses of tiagabine HCl up to 800 mg. All patients fully recovered, usually within one day. The most common symptoms reported after overdose included somnolence, impaired consciousness, agitation, confusion, speech difficulty, hostility, depression, weakness, and myoclonus. One patient who ingested a single dose of 400 mg experienced generalized tonic-clonic status epilepticus, which responded to intravenous phenobarbital.

From post-marketing experience, reports of overdose involving tiagabine HCl alone have included cases in which patients required intubation and ventilatory support as part of the management of their status epilepticus. Overdoses involving multiple drugs, including tiagabine HCl, have resulted in fatal outcomes. Symptoms most often accompanying tiagabine HCl overdose, alone or in combination with other drugs, have included: seizures including status epilepticus in patients with and without underlying seizure disorders, nonconvulsive status epilepticus, respiratory arrest, coma, loss of consciousness, ataxia, dizziness, confusion, somnolence, drowsiness, impaired speech, aggression, agitation, lethargy, myoclonus, spike wave stupor, encephalopathy, amnesia, dyskinesia, tremors, disorientation, psychotic disorder, vomiting, hostility, and temporary paralysis. Respiratory depression was seen in a number of patients, including children, in the context of seizures.

Management of Overdose: There is no specific antidote for overdose with tiagabine HCl. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage; usual precautions should be observed to maintain the airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of clinical status of the patient. Since tiagabine is mostly metabolized by the liver and is highly protein bound, dialysis is unlikely to be beneficial. A Certified Poison Control Center should be consulted for up to date information on the management of overdose with tiagabine HCl.
OBJECTIVE: The objective of this study was to investigate whether extending fusion to L4 is imperative in the surgical treatment of pediatric L5-S1 spondylolisthesis.
METHODS: This retrospective analysis encompassed 68 pediatric cases of dysplastic L5-S1 spondylolisthesis who underwent posterior lumbar interbody fusion surgery at two hospitals. Patients were categorized into two groups based on the upper instrumented vertebra (group L4 and group L5). Data were collected from medical records and radiological images obtained preoperatively and at last follow-up. Radiographic parameters including slip percentage (SP), lumbar lordosis (LL), sagittal vertical axis (SVA), pelvic incidence (PI), Spinal Deformity Study Group dysplastic lumbosacral angle (SDSG-LSA), pelvic tilt (PT), Dubousset's lumbosacral angle (Dub-LSA), sacral slope (SS), and severity index (SI) were measured. Surgery-related data and complication data were also collected. The incidence rates of complications were compared, including those of neurological deficit, adjacent-segment instability (ASI), and other complications. ASI was defined as progression of slippage > 3 mm or posterior opening > 5° in the adjacent segment. Clinical outcomes were assessed with the numeric rating scale (NRS) and the Oswestry Disability Index (ODI) scores. The follow-up period for all patients lasted a minimum of 2 years.
RESULTS: Among all 68 patients, group L4 consisted of 15 patients and group L5 comprised 53 patients. The patients included in both groups had comparable baseline demographic characteristics and radiographic parameters. Postoperative SP and SDSG-LSA were significantly lower in group L5 (p < 0.05). No other postoperative radiographic differences were observed between groups. One patient in group L4 and 3 patients in group L5 experienced transient neurological deficits (p > 0.05). There were 13 cases of ASI in group L5 compared with none in group L4 (24.5% vs 0%, p > 0.05). Of the 13 patients with ASI, 4 underwent revision surgery due to L4-5 level instability and clinical symptoms. The remaining individuals exhibited no symptoms, and regular annual follow-up assessments are being conducted for all patients. The NRS and ODI scores at final follow-up did not exhibit any significant differences between the two groups.
CONCLUSIONS: Fusion to L5 could achieve comparable satisfactory results to fixation to L4, albeit with increased likelihood of ASI. Extension of fusion to L4 may not be necessary for most patients with pediatric L5-S1 spondylolisthesis.
Patients undergoing bariatric surgery were randomly divided into two groups: one under complete intravenous anesthesia (infusion of Propofol, Ketamine, Lignocaine and Dexmedetomidine) and the other group under combined general anesthesia (infusion of Ketamine, Lignocaine and Dexmedetomidine and inhalation of Sevoflurane). In the postoperative period, all patients will receive Oxycodone NCA or in the form of oral tablets \[naloxone (naloxone hydrochloride) + oxycodone (oxycodone hydrochloride)\] and coanalgesics in the form of Paracetamol, Dexac, and Metamizol. Both methods of anesthesia are commonly used and used during bariatric and other surgical procedures. It should be emphasized once again that the above-mentioned all drugs are approved for routine use during anesthesia of patients, including obese patients, and our intervention only involves the use of a specific regimen from among those routinely available. The choice of anesthesia method depends on the anesthesiologist. During the study, we want to randomize patients into two groups: one will be anesthetized using a completely intravenous method, the other will be anesthetized using an inhalation anesthetic. Additionally, a video laryngoscope will be used to intubate half of the people for the first laryngoscopy, and a traditional laryngoscope for half of the patients, half of the patients will be randomized to each group. Both methods of visualizing the larynx and commonly used. Some centers use viedolaryngoskpie only in the case of so-called intubation. "difficult", i.e. one in which the use of a traditional laryngoscope does not allow intubation. Many bariatric surgery centers recommend the use of videolaryngoscopy routinely for the intubation of every bariatric patient. In the postoperative period, patients will have their pain level assessed using the NRS scale 1, 2, 6, 12 and 24 hours after the procedure.
IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
PROBLEM TO BE SOLVED: To obtain a makeup remover having an excellent makeup removing effect and neat use feeling, containing a sol having a specific granular diameter. SOLUTION: This makeup remover contains a sol of a metal oxide such as silica or alumina having <=200nm, preferably <=50nm, more preferably <=20nm average granular diameter in an amount of 0.1-30wt.% preferably 1-20wt.% in terms of the solid component. Besides, a volatile silicone (e.g. octamethylcyclotetrasiloxane) can be mixed in the composition. A removing effect on the makeup can be attained even if not containing a surfactant nor an oily component at all, therefore the composition can have a very neat use feeling. Different from usual makeup removers utilizing an emulsifying action of a surfactant or a solvent effect of an oily component, ultrafine granular powder in the sol in this case is adsorbed on a pigment of the makeup agent, then the pigment becomes hydrophilic and is removed.
###  MANIFESTATIONS

The most common effects associated with cyclobenzaprine overdose are drowsiness and tachycardia. Less frequent manifestations include tremor, agitation, coma, ataxia, hypertension, slurred speech, confusion, dizziness, nausea, vomiting, and hallucinations. Rare but potentially critical manifestations of overdose are cardiac arrest, chest pain, cardiac dysrhythmias, severe hypotension, seizures, and neuroleptic malignant syndrome. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of cyclobenzaprine toxicity.

Other potential effects of overdosage include any of the symptoms listed under ADVERSE REACTIONS.

###  MANAGEMENT

#### General

As management of overdose is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment.

In order to protect against the rare but potentially critical manifestations described above, obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. Observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. Monitoring of plasma drug levels should not guide management of the patient. Dialysis is probably of no value because of low plasma concentrations of the drug.

#### Gastrointestinal Decontamination

All patients suspected of an overdose with cyclobenzaprine hydrochloride should receive gastrointestinal decontamination. This should include large volume gastric lavage followed by activated charcoal. If consciousness is impaired, the airway should be secured prior to lavage and emesis is contraindicated.

#### Cardiovascular

A maximal limb-lead QRS duration of ≥0.10 seconds may be the best indication of the severity of the overdose. Serum alkalinization, to a pH of 7.45 to 7.55, using intravenous sodium bicarbonate and hyperventilation (as needed), should be instituted for patients with dysrhythmias and/or QRS widening. A pH >7.60 or a pCO2 <20 mmHg is undesirable. Dysrhythmias unresponsive to sodium bicarbonate therapy/hyperventilation may respond to lidocaine, bretylium or phenytoin. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide).
ARROW (COL105677) was a 5-year, randomized, multicenter trial which evaluated multiple aspects of clinical management of HIV-1 infection in pediatric subjects. HIV-1–infected, treatment-naïve subjects aged 3 months to 17 years were enrolled and treated with a first-line regimen containing abacavir and lamivudine, dosed twice daily according to World Health Organization recommendations. After a minimum of 36 weeks of treatment, subjects were given the option to participate in Randomization 3 of the ARROW trial, comparing the safety and efficacy of once-daily dosing with twice-daily dosing of abacavir and lamivudine, in combination with a third antiretroviral drug, for an additional 96 weeks. Virologic suppression was not a requirement for participation at baseline for Randomization 3. At baseline for Randomization 3 (following a minimum of 36 weeks of twice-daily treatment), 75% of subjects in the twice-daily cohort were virologically suppressed, compared with 71% of subjects in the once-daily cohort.

Of the 1,206 original ARROW subjects, 669 participated in Randomization 3. Subjects randomized to receive once-daily dosing (n = 336) and who weighed at least 25 kg received abacavir 600 mg and lamivudine 300 mg, as either the single entities or as abacavir and lamivudine.

The proportions of subjects with HIV-1 RNA less than 80 copies per mL through 96 weeks are shown in Table 5. The differences between virologic responses in the two treatment arms were comparable across baseline characteristics for gender and age.
OBJECTIVE: Since the mental health of older adult is an important topic in the aging society, the main purpose of this study is to understand the mental health status of the older adult in China under different conditions. More importantly, although people generally believe that leisure activities can improve mental health, the impact of these activities on older adult has not yet been fully discussed. Hence, this study further explores that what kind of leisure activity is associated with mental health of the older adult given different conditions.
METHODS: We conducted a cross-sectional questionnaire survey to explore the relationships of various leisure activities on mental health among older adults under different demographics. This study used the Geriatric Depression Scale short forms scale (GDS-15) to assess the mental health of older adults. Based on a sample of 2,006 participants, both two-sample t-test and ANOVA were adopted to analyze the characteristics of mental health among specific subsamples.
RESULTS: Our findings indicated that older adults generally have higher mental health scores if they do not have chronic diseases, live with other family members, or reside in urban. First, three leisure activities including walking, Guangchangwu, and hiking have positive associations on mental health for older adults with chronic diseases. Second, the older adults living alone engaged in Guangchangwu or hiking significantly associated with their good mental health. Finally, only Guangchangwu has a significantly positive associated with the mental health of rural older adults.
CONCLUSIONS: Based on our results, the government and healthcare planners can better allocate limited resources under different conditions to promote certain leisure activities, which are helpful to enhance the mental health of older adults. Guangchangwu is an activity that meets the characteristics of Chinese culture, so we further conclude that it is significantly associated with the good mental health of older adults in China.
Participant will receive JNJ-64565111-matching placebo on days 2, 9, 16, and 23. Participants will also receive moxifloxacin on day 1 and moxifloxacin-matching placebo on day 27 (sequence 2a) or moxifloxacin-matching placebo on day 1 and moxifloxacin on day 27 (sequence 2b) in a nested crossover manner.
Clinical follow-up for at least 6-8 hours, after follow-up repeated laboratory tests and repeated clinical examination is done. Adult Appendicitis Score is calculated after observation to determine further actions. Observation is continued in patients with decreasing score. Patients with the same or higher score undergo diagnostic imaging (score 11-15) or laparoscopy (score 16 or higher). Diagnostic imaging is abdominal ultrasound first and if the result is inconclusive or negative for appendicitis abdominal computed tomography is done. Laparoscopic appendectomy is done for those patients with appendicitis in diagnostic imaging.
A deriv. of 2H-1,2-benzothiazine, of formula (I) is made by (1) reacting a cpd. of formula (II) with a strong base (sodium methoxide) in presence of a solvent such as dimethyl sulphoxide and ring opening with a mineral acid to give a cpd. of formula (III); (2) subjecting this to ventilation with a methyl halide in solvent such as alcohol and in presence of a base such as alkali carbonate to give a cpd. of formula (IV); (3) cyclising with a metal alkoxide in a solvent such as alcohol adding HCl and ppting. with a satd. hydrocarbon to give a cpd. of formula (V); (4) hydrolysing in presence of polyphosphoric acid at 90-100 deg. C to give a cpd. of formula (VI); and (5) reacting with 2-amino pyridine in presence of BF3 and evaporating the solvent to give a cpd. of formula (I).
The present invention discloses a fish bubble disease treatment drug composition, which contains the following traditional Chinese medicines, by weight: 10-30 parts of alternanthera philoxeroides (Mart.) griseb., 12-30 parts of humifuse euphorbia herb, 2-10 parts of melia azedarach leaf, 10-25 parts of heartleaf houttuynia herb, 2-10 parts of arborvitae leaf, and 10-20 parts of tangerine peel. According to the fish bubble disease treatment drug composition, humifuse euphorbia herb, melia azedarach leaf and heartleaf houttuynia herb have effects of antibacterial and bacterial inhibition, such that the components can be adopted as effective components so as to well prevent and treat fish bubble diseases, wherein the treatment efficiency is up to 99%. According to the preparation method, alternanthera philoxeroides (Mart.) griseb. is extracted by using a supercritical CO2 extraction method, such that activities of effective components of the alternanthera philoxeroides (Mart.) griseb. are retained, and the effective component content is high. In addition, the preparation method is simple and easy to perform, and is suitable for mass production.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to gerontology and endocrinology. Substance of the method of biological age reduction in impaired glucose tolerance (IGT) consists in the fact that the IGT patient are prescribed for a long period of time with graduated static and dynamic physical activities, daily swimming in a swimming pool for at least 30 minutes a day and administration of the preparation metformin in dosage 500 mg 2 times a day. The method allows to match the biological and chronological age in the IGT patients within 7 weeks. ^ EFFECT: use of the method allows considerable improvement of life quality of the IGT patients, reduction of their pathological burden and the number of temporary disability cases, faster and better hospitalisation, lowered invalidisation and infarction and stroke induced death rate of the IGT patients. ^ 2 ex, 1 dwg
Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is characterized by hepatic fat accumulation by metabolic dysfunction. The rising prevalence of MAFLD, especially among Asians, may be associated with changes in gut microbiota. We investigated gut microbiota characteristics and potential mechanisms leading to MAFLD development according to enterotypes. Case-control studies examining the gut microbiota composition between MAFLD and non-MAFLD participants were searched in public databases until July 2023. Gut microbiota was categorized into two enterotypes by principal component analysis. According to the enterotypes, LEfSe, ALDEx2, XGBoost, and DCiPatho were utilized to identify differential abundances and pathogenic microbes in the gut between the MAFLD and non-MAFLD groups. We analyzed microbial community networks with the SprCC module and predicted microbial functions. In the Prevotella enterotype (ET-P), 98.6% of Asians and 65.1% of Caucasians were associated with MAFLD (p = 0.049). MAFLD incidence was correlated with enterotype, age, obesity, and ethnicity (p < 0.05). Asian MAFLD patients exhibited decreased Firmicutes and Akkermansia muciniphila and increased Bacteroidetes and P. copri. The pathogenicity scores were 0.006 for A. muciniphila and 0.868 for P. copri. The Asian MAFLD group showed decreased stability and complexity in the gut microbiota network. Metagenome function analysis revealed higher fructose metabolism and lipopolysaccharide (LPS) biosynthesis and lower animal proteins and α-linolenic acid metabolism in Asians with MAFLD compared with the non-MAFLD group. LPS biosynthesis was positively correlated with P. copri (p < 0.05). In conclusion, P. copri emerged as a potential microbial biomarker for MAFLD. These findings enhance our understanding of the pathological mechanisms of MAFLD mediated through the gut microbiota, providing insights for future interventions.